Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | STAT6 | P42226 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1293053 | 0.81 | TDP1 (0.52) | TDP1POLBHTTSMN1; SMN2LMNA | |
| SCHEMBL24054627 | 0.78 | HTT (0.47) | TDP1POLBHTTSMN1; SMN2LMNA | |
| SCHEMBL3968932 | 0.78 | TDP1 (0.48) | TDP1POLBHTTSMN1; SMN2LMNA | |
| SCHEMBL491202 | 0.78 | HTT (0.50) | TDP1POLBHTTSMN1; SMN2LMNA | |
| SCHEMBL160156 | 0.74 | TDP1 (0.46) | TDP1POLBHTTSMN1; SMN2LMNA | |
| SCHEMBL9529264 | 0.74 | TDP1 (0.46) | TDP1POLBHTTSMN1; SMN2LMNA | |
| SCHEMBL8901472 | 0.73 | EGLN3 (0.46) | TDP1HTTSMN1; SMN2FGFR1KMT2A | |
| SCHEMBL9446056 | 0.73 | TDP1 (0.48) | TDP1POLBHTTSMN1; SMN2LMNA | |
| SCHEMBL6392854 | 0.73 | EGLN3 (0.46) | TDP1HTTSMN1; SMN2FGFR1KMT2A | |
| SCHEMBL8003415 | 0.73 | TDP1 (0.44) | TDP1POLBHTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903978-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-109837082-B | Electroluminescent material and preparation method and application thereof | 东莞伏安光电科技有限公司 | 2022-07-26 | — | — | CN | disclosed |
| EP-3601254-B1 | QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3K-BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-25 | — | — | EP | disclosed |
| US-11267804-B2 | (R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activity | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-08 | — | — | US | disclosed |
| EP-3359533-B1 | QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-17 | — | — | EP | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| CN-109311843-B | Azabenzimidazole derivatives as PI3K beta inhibitors | 詹森药业有限公司 | 2021-10-08 | — | — | CN | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| US-11130751-B2 | Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-28 | — | — | US | disclosed |
| CN-112898254-A | Heterocyclic spiro compounds | 默克专利有限公司 | 2021-06-04 | — | — | CN | disclosed |
| US-20130157977-A1 | Benzimidazole Boronic Acid Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157977-A1 | Benzimidazole Boronic Acid Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20090005344-A1 | Compounds and Methods of Use Thereof | NKUADA, LLC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005344-A1 | Compounds and Methods of Use Thereof | NKUADA, LLC (US) | 2009-01-01 | — | — | US | disclosed |
| EP-1812451-A2 | COMPOUNDS AND METHODS OF USE THEREOF | Nuada, LLC (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1812451-A2 | COMPOUNDS AND METHODS OF USE THEREOF | Nuada, LLC (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006050053-A3 | COMPOUNDS AND METHODS OF USE THEREOF | NUADA LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006050053-A2 | COMPOUNDS AND METHODS OF USE THEREOF | NUADA, LLC (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006050053-A2 | COMPOUNDS AND METHODS OF USE THEREOF | NUADA, LLC (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2004113351-A2 | BIFUNCTIONAL AMINO-BORON LEWIS ACID - LEWIS BASE CATALYST | UNIVERSITY OF DURHAM (GB) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005344-A1 | Compounds and Methods of Use Thereof | TNF, IL1B, TNFRSF1A | TDP1 2801/4885POLB 3493/4885HTT 3529/4885 |
| US-11267804-B2 | (R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activity | PIK3CD, PIK3CA, PIK3CB | TDP1 2343/4885POLB 1652/4885HTT 3676/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | TDP1 416/4885POLB 454/4885HTT 4102/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | TDP1 478/4885POLB 272/4885HTT 3636/4885 |
| US-11130751-B2 | Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors | PIK3CA, PIK3CD, PIK3CB | TDP1 2248/4885POLB 887/4885HTT 3378/4885 |
| US-20130157977-A1 | Benzimidazole Boronic Acid Derivatives As PI3 Kinase Inhibitors | PI4KB, PI4KA, PIK3CB | TDP1 1299/4885POLB 2275/4885HTT 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.